Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
Sigaud R, Rösch L, Gatzweiler C, Benzel J, von Soosten L, Peterziel H, Selt F, Najafi S, Ayhan S, Gerloff XF, Hofmann N, Büdenbender I, Schmitt L, Foerster KI, Burhenne J, Haefeli WE, Korshunov A, Sahm F, van Tilburg CM, Jones DTW, Pfister SM, Knoerzer D, Kreider BL, Sauter M, Pajtler KW, Zuckermann M, Oehme I, Witt O, Milde T. Sigaud R, et al. Among authors: najafi s. Neuro Oncol. 2023 Mar 14;25(3):566-579. doi: 10.1093/neuonc/noac183. Neuro Oncol. 2023. PMID: 35882450 Free PMC article.
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.
Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, Jones DTW, Baßler J, Kreth S, Stainczyk S, Frese K, Meder B, Westermann F, Milde T, Peterziel H, Witt O, Oehme I. Müller M, et al. Among authors: najafi s. Cancers (Basel). 2021 Sep 5;13(17):4476. doi: 10.3390/cancers13174476. Cancers (Basel). 2021. PMID: 34503286 Free PMC article.
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models.
Gatzweiler C, Ridinger J, Herter S, Gerloff XF, ElHarouni D, Berker Y, Imle R, Schmitt L, Kreth S, Stainczyk S, Ayhan S, Najafi S, Krunic D, Frese K, Meder B, Reuss D, Fiesel P, Schramm K, Blattner-Johnson M, Jones DTW, Banito A, Westermann F, Oppermann S, Milde T, Peterziel H, Witt O, Oehme I. Gatzweiler C, et al. Among authors: najafi s. Cancers (Basel). 2022 Feb 8;14(3):849. doi: 10.3390/cancers14030849. Cancers (Basel). 2022. PMID: 35159116 Free PMC article.
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, Westermann F, Witt O, Oehme I. Shen J, et al. Among authors: najafi s. Cell Death Differ. 2018 Dec;25(12):2053-2070. doi: 10.1038/s41418-018-0080-0. Epub 2018 Mar 7. Cell Death Differ. 2018. PMID: 29515255 Free PMC article.
Investigating the effect of LncRNA DLGAP1-AS2 suppression on chemosensitivity of gastric cancer to chemotherapy.
Azadi SS, Safaralizadeh R, Amini M, Hosseinpour Feizi MA, Abdolzadeh S, Najafi S, Bahojb Mahdavi SZ, Yari A, Narimanzadeh L, Baradaran B, Mokhtarzadeh AA. Azadi SS, et al. Among authors: najafi s. Naunyn Schmiedebergs Arch Pharmacol. 2024 May 15. doi: 10.1007/s00210-024-03130-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38748228
385 results